JPS57114518A - Hypotensive agent - Google Patents

Hypotensive agent

Info

Publication number
JPS57114518A
JPS57114518A JP11749281A JP11749281A JPS57114518A JP S57114518 A JPS57114518 A JP S57114518A JP 11749281 A JP11749281 A JP 11749281A JP 11749281 A JP11749281 A JP 11749281A JP S57114518 A JPS57114518 A JP S57114518A
Authority
JP
Japan
Prior art keywords
compound
agent
hypotensive
administration
men
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP11749281A
Other languages
Japanese (ja)
Other versions
JPS591685B2 (en
Inventor
Chikao Yoshikumi
Minoru Ohara
Masanori Ubusawa
Takami Fujii
Yoshio Omura
Takao Ando
Kenichi Matsunaga
Fumio Hirose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kureha Corp
Original Assignee
Kureha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Corp filed Critical Kureha Corp
Priority to JP11749281A priority Critical patent/JPS591685B2/en
Publication of JPS57114518A publication Critical patent/JPS57114518A/en
Publication of JPS591685B2 publication Critical patent/JPS591685B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: A safe hypotensive agent, containing aminobenzoic acid-N-D-mannoside or a salt thereof, usable continuously for a long term, having a high medicinal suitability and improved hypotensive action without exhibiting the mutagenicity.
CONSTITUTION: A hypotensive agent containing a compound of formulaIor a salt thereof as an active constituent. The compound of formulaIis used in an amount of 0.001W100wt% as an active constituent in the dosage form of powder or granule. The compound may assume any oral or parenteral administration form in use as an antidiabetic agent. In use for men and animals, the agent is preferably administered orally. The oral administration includes the sublingual administration. The daily dose per kg body weight for men is preferably 1W 400mg for the oral administration and 0.1W100mg for the parenteral administration in one W divided four fractions. The compound of formula II is particularly useful.
COPYRIGHT: (C)1982,JPO&Japio
JP11749281A 1981-07-27 1981-07-27 antihypertensive drugs Expired JPS591685B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11749281A JPS591685B2 (en) 1981-07-27 1981-07-27 antihypertensive drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11749281A JPS591685B2 (en) 1981-07-27 1981-07-27 antihypertensive drugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP4257678A Division JPS54135738A (en) 1978-04-06 1978-04-11 Novel aminobenzoic acid-n-d-mannoside and drugs comprising it

Publications (2)

Publication Number Publication Date
JPS57114518A true JPS57114518A (en) 1982-07-16
JPS591685B2 JPS591685B2 (en) 1984-01-13

Family

ID=14713060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11749281A Expired JPS591685B2 (en) 1981-07-27 1981-07-27 antihypertensive drugs

Country Status (1)

Country Link
JP (1) JPS591685B2 (en)

Also Published As

Publication number Publication date
JPS591685B2 (en) 1984-01-13

Similar Documents

Publication Publication Date Title
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
NZ237904A (en) Gastric sustained release compositions comprising triclosan
GR3001284T3 (en) Pharmaceutical composition containing ibuprofen and aluminium hydroxide
JPS5759894A (en) Cephalosporin for oral administration
EP0438147A3 (en) Pharmaceutical compositions and dosage forms for the oral administration of calcitonin
JPS57140716A (en) Antiallergic agent
JPS57114518A (en) Hypotensive agent
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS57114519A (en) Antiarteriosclerotic agent
DE3164054D1 (en) Pharmaceutically acceptable salts of 4'-(9-acridinylamino) methanesulfon-m-anisidide, their production, and pharmaceutical compositions containing such salts
JPS5675428A (en) Hypoglycemic agent containing procainamide hydrochloride
JPS56115715A (en) Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative
JPS5498791A (en) Anti-asthmatic drug
JPS57114520A (en) Antiarteriosclerotic agent
JPS5675425A (en) Antitumor agent containing procainamide hydrochloride
JPS57126418A (en) Antiallergic agent
JPS5742620A (en) Novel antiulcer agent
JPS57114517A (en) Antidiabetic agent
JPS57126419A (en) Analgesic agent
JPS5675426A (en) Anti-inflammatory agent containing procainamide hydrochloride
JPS57112328A (en) Hypotensor comprising 2,3-dihydroxypropyl ester of n-(7- chloro-4-quinolyl)anthranillic acid
JPS539315A (en) Preparation of hardly soluble pharmaceuticals
JPS57112327A (en) Antidiabetic agent comprising 2,3-dihydroxypropyl ester of n-(7-chloro-4-quinolyl)anthranillic acid
JPS57128625A (en) Carcinostatic
JPS57167912A (en) Antitumor agent